4 Orkambi for CF Articles You Might Like

1 – Canadian Cystic Fibrosis Patients See Access to Orkambi Delayed for Undetermined Time

Canadian patients with cystic fibrosis will have to wait longer for access to Orkambi (lumacaftor/ivacaftor). The submission for the therapy will be reconsidered at a future meeting by the Canadian Drug Expert Committee of the Canadian Agency for Drugs and Technologies in Health.

Here are six organizations doing remarkable work either in research or with patients and their families. You can help them directly or bring awareness to them.

2. NICE Says Cost of Orkambi for Cystic Fibrosis Is Too High for Low Benefit

In March, the U.K. National Institute for Health and Care Excellence (NICE) issued a draft guidance against recommending Orkambi (lumacaftor-ivacaftor marketed by Vertex Pharmaceuticals) for treating cystic fibrosis. Read about it here.

Here are six organizations doing remarkable work either in research or with patients and their families. You can help them directly or bring awareness to them.

3. Irish CF Groups Disappointed in Government’s Funding Rejection of Orkambi as Not Cost Effective

4. #YesOrkambi – Cystic Fibrosis Advocates Campaign for Drug’s Approval in Ireland

A new social media campaign was launched in Ireland to advocate for the approval of Orkambi for cystic fibrosis (CF) patients in the country.

Here are six organizations doing remarkable work either in research or with patients and their families. You can help them directly or bring awareness to them.

Cystic Fibrosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.